Thrivent Financial For Lutherans Intra Cellular Therapies, Inc. Transaction History

Thrivent Financial For Lutherans

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 12, 2020	SELL	$14.35 - $26.64 $149,971 - $278,414	-10,451 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$12.31 - $33.12 $128,651 - $346,137	10,451 New	10,451 $161,000
Q3 2019 Nov 14, 2019	SELL	$7.47 - $14.03 $503,702 - $946,042	-67,430 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$10.65 - $14.29 $227,878 - $305,763	21,397 Added 46.48%	67,430 $875,000
Q1 2019 May 14, 2019	BUY	$10.9 - $14.09 $11,074 - $14,315	1,016 Added 2.26%	46,033 $560,000
Q4 2018 Feb 15, 2019	BUY	$10.36 - $20.96 $1,667 - $3,374	161 Added 0.36%	45,017 $513,000
Q3 2018 Nov 15, 2018	SELL	$17.77 - $22.9 $96,189 - $123,957	-5,413 Reduced 10.77%	44,856 $974,000
Q2 2018 Aug 14, 2018	BUY	$17.33 - $23.4 $4,713 - $6,364	272 Added 0.54%	50,269 $888,000
Q1 2018 May 08, 2018	BUY	$15.16 - $25.49 $9,808 - $16,492	647 Added 1.31%	49,997 $1.05 Million
Q3 2017 Nov 14, 2017	BUY	$10.77 - $22.1 $531,499 - $1.09 Million	49,350	49,350 $779,000

419

88.8M

284K

105K

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $12.4B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

Stay updated on Thrivent Financial For Lutherans with notifications on news.